1000s Evacuated As Massive Wall Of Water Surges Through Ukraine After Major Dam 'Blown Up'
Journalists Are Asking Ukrainian Soldiers To Hide Their Nazi Patches, NYT Admits
Comey: Imagine A "Retribution Presidency" Where The President Ordered The...
El Salvador Unleashes "Volcano Energy" With 241 Megawatt Planned Bitcoin Mining Operation
Newly Developed Humanoid Robot Warns About AI Creating "Oppressive Society"
Scientists develop mega-thin solar cells that could be shockingly easy to produce:
High-tech pen paints healing gel right into wounds
EG4 18K after 1 Megawatt Hour! Is it worth the $$$?
Terminator-style Synthetic Covering for Robots Mimics Human Skin and Heals Itself
The Death of 2FA (2 Factor Authentication)? + Q&A
High-speed orbital data link drags space communications out of the '60s
WORLD'S FIRST 3D PRINTED CLAY HOUSES
Smaller, cheaper, safer: The next generation of nuclear power, explained
So far, all of the drugs developed against COVID-19 have been disastrous in one way or another. Remdesivir, for example, which to this day is the primary COVID drug approved for use in U.S. hospitals, routinely causes severe organ damage, and, often, death.
Despite its horrible track record, the U.S. government actually pays hospitals a 20% upcharge for sticking to the remdesivir protocol, plus an additional bonus. Hospitals must also use remdesivir if they want liability protection.
Incentives like these have turned U.S. hospitals into veritable death traps, as more effective and far safer drugs are not allowed, and hospitals are essentially forced to follow the recommendations of the U.S. Centers for Disease Control and Prevention.
As reported by Forbes science reporter JV Chamary back in January 2021, in an article titled, "The Strange Story of Remdesivir, a COVID Drug That Doesn't Work":
"Remdesivir is an experimental drug developed by biotech company Gilead Sciences (under the brand name Veklury) in collaboration with the US Centers for Disease Control and Army Medical Research Institute of Infectious Diseases …
"The drug proved ineffective against the Ebola virus … yet was still subsequently repurposed for SARS-CoV-2 coronavirus. News media prematurely reported that patients were responding to treatment.
"But the published data later showed that 'remdesivir was not associated with statistically significant clinical benefits [and] the numerical reduction in time to clinical improvement in those treated earlier requires confirmation in larger studies' …